Long-term toxicity of the treatment for germ cell-cancer. A review

Maroto, Pablo; Anguera, Geòrgia; Martîn, Cristina

doi:10.1016/j.critrevonc.2017.11.015

Cited by 22 publications

(16 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is consistent with other reports. The increased risk of second primary cancers has been associated with the use of adjuvant therapies [20, 21]. We found an association between the use of radiotherapy and an excess risk of secondary bladder cancer, an infra-diaphragmatic site exposed to the radiotherapy field and between an excess of pancreatic cancer and treatment with chemotherapy, particularly in non-seminoma cancers.…”

Section: Discussionmentioning

confidence: 66%

Testicular cancer in Geneva, Switzerland, 1970–2012: incidence trends, survival and risk of second cancer

et al. 2019

View full text Add to dashboard Cite

Background This paper describes the testicular cancer trends for incidence, survival, socio-economic status (SES) disparities and second cancer occurrence in Geneva, Switzerland, a high-risk population. Methods We included all testicular germ-cell tumors recorded in the population-based Geneva cancer registry during the period 1970–2012. Changes in incidence trends were assessed using Joinpoint regression to calculate the annual percentage change (APC). Overall and cancer-specific survivals (OS, CSS) were estimated by Kaplan Meyer methods. To evaluate the risk of a second cancer we calculated the Standardized Incidence Ratios (SIR) using the Geneva population incidence rates. Results The average annual testicular cancer rate was 7.32/100 000 men, with a non-significant increasing trend during the study period. The highest rates were observed among men younger than 39 years. Despite a trend toward earlier diagnosis, 14% of patients were diagnosed at a late stage. Patients with non-seminoma tumours and patients with low SES were more often diagnosed with an advanced stage. Both OS and CSS improved during the study period but with strong differences by age, stage, morphology and SES. The risk for developing a second cancer was more than doubled. This risk was particularly high for a contralateral testicular cancer, bladder cancer and pancreatic cancer. Conclusions Overall, there was no substantial increase in the incidence of testicular cancer in Geneva in recent decades, however the prognosis has improved. The high risk of developing a second cancer, the differences in stage at diagnosis and survival by SES, require enhanced awareness and surveillance by clinicians, patients and men in general.

show abstract

Section: Discussionmentioning

confidence: 66%

Testicular cancer in Geneva, Switzerland, 1970–2012: incidence trends, survival and risk of second cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Type II Testicular Germ Cell Tumours (TGCTs) (seminomas and non-seminomas) are the most common testicular tumours amongst adolescents and young adults, whose incidence is constantly increasing especially in western countries [1]. Even if these cancers are characterized mainly by a good prognosis, since they are extraordinarily chemo- and radio-sensitive [2,3,4], in a small percentage of cases a cisplatin-resistance exists, making cure difficult [5]. The development of Type II TGCTs is peculiar: they origin, in fact, from a common precursor lesion, the Germ Cell Neoplasia In Situ (GCNIS), which in turn arises from the block of differentiation of Primordial Germ Cells/gonocytes [6,7,8].…”

Section: Introductionmentioning

confidence: 99%

c-Src Recruitment is Involved in c-MET-Mediated Malignant Behaviour of NT2D1 Non-Seminoma Cells

Leonetti

Gesualdi

Scheri

et al. 2019

IJMS

View full text Add to dashboard Cite

c-MET pathway over-activation is the signature of malignancy acquisition or chemotherapy resistance of many cancers. We recently demonstrated that type II Testicular Germ Cell Tumours (TGCTs) express c-MET receptor. In particular, we elucidated that the non-seminoma lesions express c-MET protein at higher level, compared with the seminoma ones. In line with this observation, NTERA-2 clone D1 (NT2D1) non-seminoma cells increase their proliferation, migration and invasion in response to Hepatocyte Growth Factor (HGF). One of the well-known adaptor-proteins belonging to c-MET signaling cascade is c-Src. Activation of c-Src is related to the increase of aggressiveness of many cancers. For this reason, we focused on the role of c-Src in c-MET-triggered and HGF-dependent NT2D1 cell activities. In the present paper, we have elucidated that this adaptor-protein is involved in HGF-dependent NT2D1 cell proliferation, migration and invasion, since Src inhibitor-1 administration abrogates these responses. Despite these biological evidences western blot analyses have not revealed the increase of c-Src activation because of HGF administration. However, notably, immunofluorescence analyses revealed that cytoplasmic and membrane-associated localization of c-Src shifted to the nuclear compartment after HGF stimulation. These results shed new light in the modality of HGF-dependent c-Src recruitment, and put the basis for novel investigations on the relationship between c-Src, and TGCT aggressiveness.

show abstract

“…Other chemotherapyrelated multi-system side effects like cardiovascular disease, leukyemia, etc. were also reported by some researchers (8)(9)(10)(11). Every sword has its two sides, advantages and disadvantages of chemotherapy should be evaluated comprehensively.…”

Section: Discussionmentioning

confidence: 85%

Clinical Characteristics of Testicular Nonseminomatous Germ Cell Tumor from West China: A 10-Year Experience of a Super regional Center

Chen

Wang

Cao

et al. 2019

Preprint

View full text Add to dashboard Cite

Obejectives: To evaluate the clinical characteristics and prognostic factors of Nonseminomatous Germ Cell Tumor (NSGCT). Patients and methods: Testicular cancer (TC) survey was conducted by Department of Urology, West China Hospital from 2008 to 2018. Details such as age, tumor size, tumor markers, histopathology, clinical stage, initial treatment, follow up, and clinical outcomes were provided by the database of our center. Tumor stage was classified according to the NCCN criteria(1). Results: Orchiectomy, chemotherapy and radio-therapy were the main treatments for these patients. Clinical stage I, stage II and stage III patients accounted for 74.6% (150), 7.5% (15) and 17.9% (36), respectively. After a median follow up time of 63 months, 4 patients relapsed during observation and 3 of them died. 4 patients died because of advanced malignancies. Among CSI patients, 2 relapsed and 1 died in 3 months after orchiectomy. No recurrence was found in CSII patients. 2 out of 29 stage III cases relapsed after treatment and 3 died of advanced cancer. The 3- and 10- year OS was 95.6% and 88.7%, respectively. For all the patients, the 3- and 10-year PFS was 94.9% and 88.8%. According to our data, we found that the meatastasis and tumor size were risk factors for NSGCTs. Conclusion: The present report showed a good prognosis at non-metastatic stage(CSI). However, the prognosis of advanced disease(CSII and CSIII) is significantly worse than that of early stage. We also found that maximum tumor diameter of >5cm was a potential risk factor for NSGCT.

show abstract

Long-term toxicity of the treatment for germ cell-cancer. A review

Cited by 22 publications

References 66 publications

Testicular cancer in Geneva, Switzerland, 1970–2012: incidence trends, survival and risk of second cancer

Testicular cancer in Geneva, Switzerland, 1970–2012: incidence trends, survival and risk of second cancer

c-Src Recruitment is Involved in c-MET-Mediated Malignant Behaviour of NT2D1 Non-Seminoma Cells

Clinical Characteristics of Testicular Nonseminomatous Germ Cell Tumor from West China: A 10-Year Experience of a Super regional Center

Contact Info

Product

Resources

About